Nuvectra Corporation (NASDAQ:NVTR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
|
Entry into a Material Definitive |
Effective July 1, 2017, Neuronexus Technologies, Inc., a
wholly-owned subsidiary of Nuvectra Corporation (Neuronexus)
entered into a Business Property Lease Agreement (the Lease
Agreement) with BMT Ann Arbor, LLC (Landlord) to lease
approximately 9,970 square feet of space for the operations and
main offices for Neuronexus. Under the terms of the Lease
Agreement, Neuronexus will lease the space located in Ann Arbor,
Michigan for 60 months beginning on July 1, 2017 and expiring on
June 30, 2022 at a cost of $11,000.00 per month.
The foregoing description is not complete and is qualified in its
entirety by reference to the full text of the Lease Agreement,
which is filed as Exhibit 10.1 to this Current Report and
incorporated by reference into this Item 1.01.
|
Item9.01 |
|
Financial Statements and Exhibits. |
(d)Exhibits.
|
10.1 |
|
Business Property Lease Agreement, dated July 1, 2017, |
Nuvectra Corp ExhibitEX-10.1 2 ex10-1.htm EXHIBIT 10.1 ex10-1.htm Exhibit 10.1 BUSINESS PROPERTY LEASE BMT Ann Arbor,…To view the full exhibit click here About Nuvectra Corporation (NASDAQ:NVTR)
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company’s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
